PAVmed Inc Cash Flow Conversion Efficiency
PAVmed Inc cash flow conversion efficiency. Based on the latest financial reports, PAVmed Inc (PAVM) has a cash flow conversion efficiency ratio of -0.035x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-896.00K) by net assets ($25.79 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of PAVmed Inc (2014–2024)
Cash flow conversion efficiency of PAVmed Inc from 2014 to 2024. This chart illustrates how PAVmed Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. View PAVmed Inc stock quote for real-time trading data and today's change.
PAVmed Inc Cash Flow Conversion Ratio Explained
PAVmed Inc cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
PAVmed Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of PAVmed Inc ranked by their cash flow conversion efficiency. Also see PAVmed Inc (PAVM) total market value for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
KATORO GOLD PLC LS-01
F:622
|
N/A |
|
Spectur Ltd
AU:SP3
|
-0.224x |
|
Northern 3 Vct Plc
LSE:NTN
|
-0.021x |
|
Digital Ally Inc
NASDAQ:DGLY
|
-0.047x |
|
Elixinol Wellness Ltd
AU:EXL
|
-0.246x |
|
AnalytixInsight Inc
V:ALY
|
-0.001x |
|
Lord Resources Ltd
AU:LRD
|
-0.211x |
|
Goldcliff Resource Corp
V:GCN
|
-0.238x |
Annual Cash Flow Conversion Efficiency for PAVmed Inc (2014–2024)
The table below shows the annual cash flow conversion efficiency of PAVmed Inc from 2014 to 2024. Review PAVM free cash flow to operating cash ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-7.03 Million | $-33.55 Million | 4.771x | +120.21% |
| 2023-12-31 | $-24.02 Million | $-52.04 Million | 2.167x | +133.37% |
| 2022-12-31 | $10.93 Million | $-70.98 Million | -6.492x | -1170.21% |
| 2021-12-31 | $79.42 Million | $-40.59 Million | -0.511x | -101.10% |
| 2020-12-31 | $-473.00K | $-21.91 Million | 46.330x | +1508.74% |
| 2019-12-31 | $-4.64 Million | $-13.36 Million | 2.880x | -18.85% |
| 2018-12-31 | $-2.48 Million | $-8.79 Million | 3.549x | +52.97% |
| 2017-12-31 | $-2.85 Million | $-6.61 Million | 2.320x | -83.38% |
| 2016-12-31 | $-319.07K | $-4.45 Million | 13.962x | +808.29% |
| 2015-12-31 | $633.92K | $-1.25 Million | -1.971x | -2499.63% |
| 2014-12-31 | $794.83K | $-60.27K | -0.076x | -- |
About PAVmed Inc
PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing… Read more